Objetivo
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:
“A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.”
Ámbito científico
- medical and health scienceshealth sciencespublic health
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesebola
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Palabras clave
Programa(s)
Tema(s)
Convocatoria de propuestas
H2020-JTI-IMI2-2015-08-single-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
WC1E 7HT London
Reino Unido